Research
Cellular
Total hip (TH) bone loss was comparable between GLP-1 RA users and controls among patients with diabetes mellitus (DM).
Bone health monitoring may be less critical for patients with DM using GLP-1 RAs.
StrongSupportsmedium confidence
TH bone loss was similar between groups among patients with DM.
Why this rating
Based on a retrospective study design with matched controls.
Source
Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
Yi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2026
DOI 10.1210/clinem/dgag052
cohort · n=510Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (SEM) and tirzepatide (TIR) use was associated with greater annualized total hip (TH) bone loss in patients without diabetes mellitus (DM) compared to controls.Strong
- Weight loss in the GLP-1 RA group was directly associated with bone loss at the total hip (TH) and femoral neck (FN).Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →